Background 

This study focuses on how antibodies—proteins our bodies make to fight infections—can be used to help treat bladder cancer. Scientists can now make antibodies in the lab, called recombinant antibodies, that are designed to target the immune system to help it fight cancer. These lab-made antibodies have already helped many cancer patients live longer, including some with bladder cancer. However, not everyone benefits from these treatments, and researchers want to understand why. 

The research team is studying a new way to help the immune system attack bladder cancer. While many treatments focus on removing the “brakes” that slow down immune cells, this team is trying a different method—pushing the “gas pedal” to make the immune system stronger. They are focusing on a specific protein called CD40 that may help boost immune cell activity against bladder cancer. 

What the Study Proposes to Address 

The researchers have developed a new antibody in the lab that targets CD40. They want to learn how CD40 works within the immune system of people with bladder cancer and test how this new antibody might be used as a treatment, especially for patients with early-stage disease. To do this, they will use human tissue samples and special “humanized” mouse models that closely mimic how the human immune system works. 

Why This Research Is Important 

This research could open the door to a new way of treating bladder cancer by strengthening the immune system instead of just unblocking it. If successful, this approach could help more patients benefit from immunotherapy, especially those whose cancer doesn’t respond well to current treatments. The team hopes their work will eventually lead to better, longer-lasting results for people fighting bladder cancer. 

Final Report Summary 

Researchers have discovered a new way to treat early-stage bladder cancer by targeting a protein called CD40. This protein plays an important role in helping the immune system recognize and attack cancer cells. The team created a special kind of medicine called a monoclonal antibody that has been designed to make CD40 work even better. 

When this antibody was placed directly into the bladder, it triggered a strong immune response against bladder cancer in both new and previously treated cases. This method is important because giving CD40 treatments through the bloodstream can sometimes cause harmful side effects, but delivering it straight into the bladder avoids those problems. 

The results were promising—this treatment not only removed the first tumors but also prevented new ones from coming back months later. This means it could lead to long-lasting protection for patients. The researchers are now testing this therapy in a clinical study for patients whose cancer did not respond to BCG treatment at Memorial Sloan Kettering Cancer Center in New York. They are also exploring whether combining the CD40 antibody with another immune-boosting substance called IL-15 can make the treatment even more effective. 

Garris, C. S., Wong, J. L., Ravetch, J. V., & Knorr, D. A. (2021). Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer. Science translational medicine, 13(594), eabd1346. https://doi.org/10.1126/scitranslmed.abd1346

None Reported as of August 2025

David Knorr, MD, PhD; The Rockefeller University